+ Watch NVS
on My Watchlist
Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products.
good solid company.
Good mix of products. Good management.
diversified healthcare company will become the largest healthcare (pharma) company in the world in terms of revenue
NVS has an enviable strategic position with a nice pipeline of late-stage products. Diversified product lines buffer the company from difficulties in any one segment. NVS also benefits from increased adoption of generic drugs. Steady, defensive big pharma play with a good margin of safety at current levels.
Another Euro drug manufacturer that now does generic stuff. Cheap and about to go higher.
lack of patent protection overhyped
pharmy and generic pipeline, biotech, plus optical
Novartis is the world's third largest pharmaceutical company with blockbuster products such as Glivec/Tasigna (cancer) and Gilenya (multiple sclerosis). PE at 9.6 and a net dividend yield of 4.8%. The market will reflect that.
one of best pharma, good dividend
A reasonably safe bet. The management is finished destroying value through acquisitions: the last cash that remained to be squandered has been squandered last year, and during a debt crisis nobody will lend them money for the next purchase. That leaves us with a low PE, and with speculators assuming (mistakenly) that with no more empire building the "E" will finally accrue to them. This illusion will put a floor under the price, especially when the "E" is stable and speculators are desperately looking for stability.
Excellent company, great dividend analysis.
Swiss Compant + Decent Yield + Pharma
It is a good day to buy European stocks (even cheaper than when I bought it.)
Has exposure to both patented and generic medicine.Good balance sheet.Should move up after Alcon acquisition is complete.
Solid in recession, solid outside of recession.
One part of my health care triple play. Novartis is a pharmaceutical company with a nice dividend, international reach, and generic drug presence. Generics are the wave of the future and any company that can provide lower price medication for an emerging international market community is a strong long term play. Health care will see significant growth going forward, I want in on all aspects of the industry.
Undervalued? Maybe, but with some new FDA approvals there should be ample opportunity for growth
NVS, Novartis, 119, 418 employees, based in Basel, Switzerland. Debt/equity of 0.36, market cap of 126.26 billion, relatively low price/earnings ratio as compared to others in industry, of 12.95. Diversified interests include vaccines, infectious disease treatment, and specifically, over-the-counter (OTC) drugs, animal health, and vision products.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions